Ophthalmo-Evercil is considered relevant for managing symptoms related to physical discomfort and supporting clinical procedures. The foundation of its therapeutic purposes is aligned with its core ingredient, which may assist with pupil dilation for various eye examinations.

This medication is commonly used to help address ocular congestion and visible redness (hyperemia) resulting from minor, non-specific eye irritation, contributing to improved day-to-day comfort. Its clinical relevance is also relevant for supportive assistance with diagnostic fundus examinations and pre- and post-operative management around complex surgeries like cataract extraction.

It is applied in the therapeutic management of certain inflammatory conditions, such as uveitis, where it may assist with managing the risk of structural complications like posterior synechiae formation. The combination of actions supports patients during episodes of heightened discomfort and is considered relevant for easing challenging symptomatic phases.

“The drops are commonly used when short-term symptomatic assistance is needed and may assist in providing required functional assistance for clinical needs.”

Quick Fact: Symptomatic Relief for Ocular Redness
This solution is relevant for addressing the visible symptom of hyperemia, which is the appearance of bloodshot eyes often associated with episodic, non-specific irritation.

Regulatory References

1. indicated to dilate the pupil

Eligibility Profile: Who Can and Cannot Use This Medicine

Official regulatory documents define strict population eligibility for Ophthalmo-Evercil, primarily due to the systemic effects of its active component, Phenylephrine Hydrochloride.

Contraindicated Populations (Absolute Ban)	Restricted/Conditional Use
Patients with closed angle glaucoma or a narrow angle prone to mydriatic-precipitated glaucoma.	Use with caution in patients over 65 years of age and in those with diabetes or cerebral arteriosclerosis.
Patients with known hypersensitivity to any component of the formulation.	Patients with cardiovascular disease should use the 2.5% strength only, not the 10% strength.

Age-Related and Comorbidity Restrictions: The 10% strength solution is contraindicated in patients with hypertension or thyrotoxicosis (hyperactive thyroid). This higher strength is also contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. For patients over one year, use of the 10% solution requires caution, especially in children less than five years old.

Pregnancy and Lactation: Safety for use during pregnancy and lactation has not been established. The medicine should be administered to a pregnant woman only if clearly needed, and caution should be exercised when administered to a nursing woman, according to official labeling.

The official regulatory profile for Ophthalmo-Evercil interactions is defined primarily by the sympathomimetic component, Phenylephrine, and the risk of severe pharmacodynamic synergy. This interaction structure establishes constraints on co-administration with specific medicinal products, emphasizing the potential for enhanced cardiovascular responses.

Documented Interaction Patterns

Interaction Type	Interacting Agents/Classes	Official Outcome Description
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Risk of severe hypertensive reactions or hypertensive crisis.
Pharmacodynamic Synergy	Atropine-like Drugs	Exaggeration of pressor effects and induction of tachycardia.
Pharmacodynamic Synergy	Potent Inhalation Anesthetic Agents	Potentiation of cardiovascular depressant effects.

Interaction-Related Restrictions

The most stringent regulatory restriction is the prohibition of concomitant use with MAOIs. The official label specifies that the risk of serious systemic adverse reactions, including marked blood pressure elevation, is noted as being higher in patients with pre-existing conditions such as Cardiovascular Disease or Hyperthyroidism. Furthermore, the 10% strength of the active substance is specifically noted as contraindicated in pediatric patients less than one year of age due to the increased risk of systemic toxicity. No interactions with foods, alcohol, or supplements are formally documented for the ophthalmic route.

How Ophthalmo-Evercil Works: Dual Mechanistic Domains

Ophthalmo-Evercil operates through two distinct yet complementary pharmacological mechanistic domains to influence ocular microcirculation and muscle function.

---

alpha1-Adrenergic Receptor-Mediated Vasoconstriction

This mechanism is driven by Phenylephrine, which acts as a direct agonist on the alpha1-adrenergic receptors found in the eye's smooth muscle, initiating a cascade that rapidly increases intracellular calcium (C a^2+). The resultant smooth muscle contraction causes vasoconstriction of local vessels and induces mydriasis (pupil dilation) via the contraction of the iris radial muscle.

---

Vascular Wall Integrity and Stabilization

The secondary mechanism involves Esculin, a molecule that modulates enzymes responsible for degrading the Extracellular Matrix components of the vessel wall. This mechanism reduces the degradation of the endothelial barrier and perivascular components, resulting in decreased permeability of the capillary wall to fluid and proteins. This dual action facilitates physiological adjustments to both smooth muscle tone and microvascular structure.

Administration of Ophthalmo-Evercil

Ophthalmo-Evercil is a solution intended for ophthalmic use. Proper administration is essential to ensure the solution remains sterile and effective throughout the duration of its use.

Preparation and Hygiene

Before handling the medication, it is necessary to wash hands thoroughly with soap and water. This practice helps prevent the introduction of bacteria or other contaminants into the eye or onto the dropper tip.

Application Technique

To apply the drops, the head should be tilted back slightly while looking upward. By gently pulling the lower eyelid down, a small pocket is created to receive the solution. The bottle is held inverted above the eye, ensuring that the dropper tip does not come into contact with the eye, eyelids, eyelashes, or any other surfaces. Contact with surfaces can contaminate the remaining solution in the bottle.

After the drop is instilled, the eye should be closed gently. Applying light pressure to the inner corner of the eye (near the nose) for a short period can help keep the solution in contact with the ocular surface. If the solution is being used in both eyes, the process is repeated for the second eye.

Handling and Storage

The container must be closed tightly immediately after each use. The dropper tip is designed to deliver a specific volume; therefore, it should not be wiped or rinsed. If any excess liquid remains on the skin around the eye, it can be gently patted dry with a clean tissue.

If multiple types of eye drops are being used, a specific interval of time is typically maintained between the application of different products to prevent one solution from washing out the other. If contact lenses are worn, they are generally removed prior to application and reinserted after a designated period, unless otherwise specified by the product characteristics.

The research on Ophthalmo-Evercil focuses on how its components are studied for specific needs in eye care, primarily in the areas of pupil dilation, symptomatic relief, and the management context of certain inflammatory conditions. The evidence base provides context regarding what has been studied and what remains uncertain.

---

Evidence for Mydriasis (Pupil Dilation) in Clinical Procedures

Research has extensively examined how this medicine may influence the pupil for achieving pupil dilation (mydriasis), necessary for eye examinations and surgical procedures. Randomized Controlled Trials (RCTs) and controlled studies monitored outcomes like millimeter changes in Pupillary Diameter and recovery time. Findings describe patterns observed in the studies in both Adults and Preterm Infants. However, long-term research is limited to the immediate period of observation, and the specific contribution of the Esculin component is not fully characterized for this objective.

---

Evidence for Temporary Relief of Ocular Redness and Congestion

The medicine was studied for its potential role in observing changes related to ocular redness (hyperemia) and congestion, which may be associated with minor irritation. Controlled Clinical Studies monitored outcomes such as a change in the diameter of conjunctival blood vessels. Findings reporting patterns consistent with a temporary physiological imbalance was observed in some studies. Large-scale, dedicated RCTs focusing specifically on patient-reported outcomes for subjective redness relief compared to placebo are still emerging.

---

Evidence for Symptomatic Assistance in Uveitis Management

Research has explored the medicine's use in providing symptomatic assistance during the management context of inflammatory conditions like Iridocyclitis. This evidence is derived from small-scale clinical studies which evaluated outcomes related to physical discomfort and changes in inflammatory markers. The findings were mixed and demonstrated limited efficacy in certain study subgroups.

---

What Remains Uncertain About Ophthalmo-Evercil Research

A review of the evidence highlights several areas where certainty remains low and research is ongoing. The primary uncertainty relates to the limited information for long-term outcomes across all indications, as follow-up durations are overwhelmingly short-term. The research base also lacks sufficient data for certain groups, such as pregnant populations or those with specific comorbidities. Furthermore, the distinct role of the Capillary Stabilizer (Esculin) in the combination is an area where more dedicated clinical trials are needed.

Key Studies & References

1. Phenylephrine Hydrochloride Ophthalmic Solution, USP (U.S. National Library of Medicine/DailyMed Regulatory Label)
2. Ophthalmic Agents for Ocular Hyperemia and General Uses - StatPearls [Internet]
3. Mydriatic agents in clinical ophthalmology: A review of current practices and research (Representing High-Level Mydriasis Evidence)

Common questions about Ophthalmo-Evercil (FAQ)

Q: Is Ophthalmo-Evercil a common or first-line treatment for eye redness?

A: Official documents describe the medicine's purpose as helping to facilitate eye examinations by dilating the pupil, and also providing temporary relief from ocular redness and congestion. Regulatory labeling does not classify the medicine as 'common' or 'first-line,' but describes its approved uses for these specific conditions.

Q: Is Ophthalmo-Evercil available over the counter?

A: According to official product information and packaging details, this medicine is designated as a prescription-only product. It requires a prescription from a healthcare professional for its use.

Q: How quickly does Ophthalmo-Evercil begin to work?

A: Studies noted in the regulatory documents indicate that the medicine's maximum effect, specifically the maximal pupil dilation (mydriasis), typically occurs between 20 to 90 minutes after the application of the solution.

Q: Are the reported side effects of Ophthalmo-Evercil usually temporary?

A: The official product label describes ocular (eye-related) adverse reactions, such as stinging on instillation and temporary blurred vision, as documented effects. However, the effect of pupil dilation (mydriasis) may last for several hours, and the duration of other side effects can vary.

Q: What is the overall effectiveness of Ophthalmo-Evercil according to research?

A: Clinical studies have examined the medicine’s effectiveness in achieving pupil dilation necessary for eye procedures and for the temporary relief of ocular redness and congestion. Official labeling supports the medicine's use for these purposes, but does not provide a single statement summarizing an 'overall effectiveness' claim.

Q: Are there any documented interactions between Ophthalmo-Evercil and common over-the-counter pain relievers?

A: Regulatory documents list interactions with specific drug classes, such as MAOIs and certain anesthetic agents, due to the sympathomimetic component of the medicine. There are no formally documented interactions between Ophthalmo-Evercil and common non-prescription pain relievers for the ophthalmic (eye drop) route.

Q: Does Ophthalmo-Evercil need to be kept refrigerated?

A: Official instructions specify that the medicine should be stored at controlled room temperature, typically between 20, C and 25, C. It is explicitly instructed to avoid freezing the solution.

Q: Is Ophthalmo-Evercil suitable for people who wear soft contact lenses?

A: Official product information notes that the formulation contains benzalkonium chloride (BAK), a preservative that can be absorbed by soft contact lenses. Regulatory patient information often includes the recommendation to remove contact lenses prior to application.

Q: What are the major warnings about Ophthalmo-Evercil for patients?

A: Warnings highlighted in regulatory documents include the potential for serious cardiovascular reactions, significant elevations in blood pressure, and the risk of potentially leading to acute closed-angle glaucoma (a sudden spike in eye pressure) in susceptible individuals.

Q: What are the ingredients in Ophthalmo-Evercil besides the active medicine?

A: In addition to the two active ingredients, Phenylephrine Hydrochloride and Esculin, official documents list inactive ingredients. These typically include buffers, such as sodium phosphate monobasic and dibasic, and a preservative like benzalkonium chloride.

Q: Is there a known effect of Ophthalmo-Evercil on night vision?

A: Due to the medicine's action of dilating the pupil (mydriasis), which can last for several hours, it may cause temporary sensitivity to light (photophobia). Regulatory information indicates that patients may be instructed to protect their eyes from bright illumination during the period of pupil dilation.

Q: Is there a generic version of Ophthalmo-Evercil available?

A: Official drug product databases indicate that the active components found in this medicine are available in generic formulations.

Q: Can Ophthalmo-Evercil be used for other eye conditions besides its main uses?

A: Official regulatory documents define the medicine's approved uses as pupil dilation for ophthalmic procedures and temporary relief of ocular redness and congestion. The medicine should only be used as indicated in the official labeling.

Q: How long does a bottle of Ophthalmo-Evercil usually last for a typical user?

A: The medicine is intended for short-term, as-needed use to facilitate a procedure. The official label specifies that, regardless of how many applications have been used, the solution must be discarded after a short labeled period (typically 28 days) following initial opening to maintain sterility.

Q: Is Ophthalmo-Evercil a steroid or a non-steroid medication?

A: Ophthalmo-Evercil is classified as a sympathomimetic agent (alpha1-adrenergic receptor agonist) and a capillary stabilizer. Based on its pharmacological classification in regulatory documents, it is not classified as a steroid.

Q: Can Ophthalmo-Evercil be used by children?

A: The use of this medicine is addressed in pediatric patients, but with specific restrictions. Regulatory information contraindicates the higher 10% strength in children less than one year of age due to an increased risk of systemic toxicity.

Q: What is the risk of having a serious allergic reaction to Ophthalmo-Evercil?

A: The medicine is contraindicated (should not be used) in patients with a known hypersensitivity to any of its components. Allergic contact reactions have been reported in post-marketing surveillance.

Q: Do people who have had cataract surgery use Ophthalmo-Evercil?

A: The medicine is indicated to dilate the pupil (mydriasis) for ophthalmic procedures. This includes pre-operative use for certain surgeries, as the dilation helps the specialist gain a clearer view.

Q: How does the evidence for Ophthalmo-Evercil compare to placebo in clinical studies?

A: Clinical studies have been conducted to evaluate the medicine's effects, sometimes comparing it to other agents or examining the dose required to achieve the desired response. Specific comparisons to placebo are detailed in the clinical studies section of the official regulatory label.

Q: Is Ophthalmo-Evercil used for both acute and chronic eye conditions?

A: The official administration guidelines describe the medicine’s use as short-term, intended for administration only as required to facilitate diagnostic or therapeutic procedures or for temporary symptomatic relief. It is not intended for chronic, long-term use.

Q: What should be done if Ophthalmo-Evercil is accidentally applied incorrectly?

A: Regulatory patient information describes that if the medicine is accidentally swallowed, medical attention or contact with a Poison Control Center is warranted.

Q: Does Ophthalmo-Evercil expire quickly after initial opening?

A: Official labeling instructs that as a sterile product, the solution must be discarded after a specific period following the initial opening, typically 28 days, to ensure the product remains sterile.

Q: Is the medication absorbed into the body after application?

A: Regulatory information indicates that systemic absorption (absorption into the rest of the body) occurs following topical application to the eye. This absorption is what can lead to systemic effects, such as a rise in blood pressure, and is expected to be higher with the 10% solution.

Q: What are the long-term effects of using Ophthalmo-Evercil?

A: Regulatory reviews of the evidence indicate that research on the long-term outcomes of this medicine is limited. Follow-up durations in clinical studies are overwhelmingly short-term, corresponding to its use for acute procedures and temporary relief.

Q: Is Ophthalmo-Evercil described as safe for use during pregnancy?

A: Safety for use during pregnancy has not been definitively established. Official documents state that it is unknown if the medicine can cause fetal harm, and it should be administered to a pregnant woman only if clearly needed.

Q: Is Ophthalmo-Evercil described as safe for use while breastfeeding?

A: It is not known whether the medicine is excreted in human breast milk. Official labeling recommends that caution should be exercised when the medicine is administered to a nursing woman.

Q: What percentage of people experience side effects from Ophthalmo-Evercil?

A: In regulatory documents, many adverse reactions are categorized as having a 'frequency unknown' or 'frequency not reported.' This is common for medicines, as the data often relies on voluntary post-marketing surveillance reports rather than exact percentages from initial clinical trials.

Q: Can Ophthalmo-Evercil interact with contact lens solutions?

A: The medicine contains a preservative that may be absorbed by soft contact lenses. Regulatory patient counseling information typically includes a recommendation that contact lenses be removed prior to application.

How to Store and Dispose of Ophthalmo-Evercil?

Ophthalmo-Evercil, as a sterile ophthalmic solution, must be stored under specific environmental and safety conditions defined in regulatory labeling.

Storage and Stability

• Temperature: Store at controlled room temperature, typically between 20, C and 25, C, and do not freeze.
• Protection: The medicine must be kept in its original container, tightly closed, and stored away from light.
• Child Safety: It is required to store the eye drops out of the sight and reach of children.
• In-Use Period: As a sterile product, the solution must be discarded after a short labeled period, typically 28 days, following the initial opening.

Disposal Instructions

Unused or expired Ophthalmo-Evercil should be disposed of primarily through an authorized drug take-back program. It is a mandatory instruction to not pour the medicine down the drain or flush it into the toilet unless explicitly authorized by the regulator. If a take-back program is unavailable, the solution should be mixed with an undesirable substance and sealed before being placed in household trash.